The company announced on 20 July that it had begun the review, which could also involve a merger or the decision to retain the operation. IBA said it would provide an update on its plans by the end of 2018.

The vendor said that IBA Dosimetry saw strong growth in 2017, which has enabled the company to "maximize the future value and strategic potential of this business" as it seeks to focus on its core proton therapy and linear accelerator business.